OKYO
Income statement / Annual
Last year (2026), OKYO Pharma Limited's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2026, OKYO Pharma Limited's net income was -$8.95 M.
See OKYO Pharma Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2026
|
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
03/31/2026 |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$6.69 M
|
$2.56 K
|
$7.51 M
|
$6.75 M
|
$13.00 K
|
$811.50 K
|
$5.97 K
|
$219.17
|
$0.00
|
$0.00
|
| Gross Profit |
-$6.69 M
|
-$2.56 K
|
-$7.51 M
|
-$6.75 M
|
-$13.00 K
|
-$811.50 K
|
-$5.97 K
|
-$219.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$1.81 M
|
$2.25 M
|
$8.24 M
|
$6.34 M
|
$1.61 M
|
$348.35 K
|
$517.46 K
|
$3.04 M
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$573.43 K
|
$363.20 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$0.00
|
$4.93 M
|
$0.00
|
$6.75 M
|
$4.93 M
|
$2.97 M
|
$995.42 K
|
$1.85 M
|
$573.43 K
|
$363.20 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$6.75 M
|
-$320.00 K
|
$0.00
|
$0.00
|
-$15.81 K
|
-$12.43 K
|
$0.00
|
| Operating Expenses |
$1.81 M
|
$7.19 M
|
$8.24 M
|
$6.34 M
|
$6.22 M
|
$3.32 M
|
$1.51 M
|
$4.54 M
|
$985.82 K
|
$363.27 K
|
| Cost And Expenses |
$8.50 M
|
$7.19 M
|
$15.75 M
|
$13.09 M
|
$6.22 M
|
$4.13 M
|
$1.50 M
|
$4.54 M
|
$28.29 M
|
$363.27 K
|
| Interest Income |
$32.10 K
|
$5.47 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$48.07 K
|
$0.00
|
$0.00
|
$4.42 K
|
| Interest Expense |
$473.94 K
|
$883.65 K
|
$1.05 M
|
$96.69 K
|
$0.00
|
$1.12 K
|
$1.16 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.82 K
|
$2.56 K
|
$3.87 K
|
$3.80 K
|
$2.33 K
|
$13.11 K
|
$5.97 K
|
$217.82
|
$104.61 M
|
$52.52 K
|
| EBITDA |
-$8.47 M |
-$7.08 M |
-$15.75 M |
-$13.08 M |
-$6.22 M |
-$4.12 M |
-$1.51 M |
-$4.54 M |
$26.17 M |
-$363.00 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$442.12 K
|
-$781.20 K
|
-$1.05 M
|
-$196.42 K
|
$13.00 K
|
$754.84 K
|
-$99.49 K
|
-$363.00 K
|
-$12.44 K
|
$121.34 K
|
| Income Before Tax |
-$8.94 M
|
-$7.97 M
|
-$16.80 M
|
-$13.28 M
|
-$6.22 M
|
-$3.38 M
|
-$1.62 M
|
-$4.90 M
|
-$28.27 M
|
-$242.00 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$7.99 K
|
-$3.26 M
|
$22.42 K
|
-$12.00 K
|
-$787.00 K
|
-$25.00 K
|
-$76.19 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$8.95 M
|
-$4.71 M
|
-$16.83 M
|
-$13.27 M
|
-$5.43 M
|
-$3.35 M
|
-$1.54 M
|
-$4.90 M
|
-$28.30 M
|
-$243.00 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.24 |
-0.12 |
-0.0006 |
-0.6 |
-0.36 |
-0.32 |
-0.17 |
-0.62 |
-4.8 |
-0.0413 |
| EPS Diluted |
-0.24 |
-0.12 |
-0.0006 |
-0.6 |
-0.36 |
-0.32 |
-0.17 |
-0.62 |
-4.8 |
-0.0413 |
| Weighted Average Shares Out |
$37.36 M
|
$39.49 M
|
$29.34 M
|
$22.26 M
|
$15.06 M
|
$10.35 M
|
$9.16 M
|
$7.91 M
|
$5.89 M
|
$5.86 M
|
| Weighted Average Shares Out Diluted |
$37.36 M
|
$39.49 M
|
$29.34 M
|
$22.26 M
|
$15.06 M
|
$10.35 M
|
$9.16 M
|
$7.91 M
|
$5.89 M
|
$5.86 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
